Insulin-like growth factor (IGF)-binding protein-2 (IGFBP-2) is altered in different diseases and might be used as an indication of its severity. The aims of our study were to investigate: (1) the developmental pattern of the serum IGFBP-2 concentration at birth and during childhood and adolescence; (2) whether the serum IGFBP-2 level could be a marker for the diagnosis and evolution of diseases where the growth hormone (GH)-IGF axis is altered, and (3) whether this binding protein shows a relationship with IGF-I, its free fraction, IGFBP-1 and -3. We report reference values for 55 normal full-term newborns and 221 normal children who were divided into 5 groups according to their Tanner stage. Serum levels were higher in newborns when compared with Tanner stages I–V (p < 0.001, ANOVA), with no further changes throughout development. Furthermore, we studied IGFBP-2 levels in 24 children with congenital GH deficiency (GHD), 26 with acute lymphoblastic leukemia (ALL), 75 obese children, and 60 girls with anorexia nervosa (AN) at diagnosis and during a follow-up period. IGFBP-2 at diagnosis was increased in GHD, ALL and AN, and decreased in obesity (p < 0.05, ANOVA). During the follow-up, IGFBP-2 concentrations tended to normalize. IGFBP-2 correlated positively with IGFBP-1 and negatively with IGF-I and IGFBP-3 in normal subjects and at diagnosis of the pathologies studied. Although IGFBP-2 functions are not well understood, these results suggest a possible role for this protein in diseases where the GH-IGF axis is altered.

Keywords:
Insulin-like growth factor-binding protein-2, Growth hormone deficiency, Obesity, Anorexia, Leukemia
1.
Baserga R, Prisco M, Hongo, A. IGFs and cell growth; in Rosenfeld RG, Roberts CT Jr (eds): The IGF System: Molecular Biology, Physiology, and Clinical Applications. Totowa, Humana Press, 1999, pp 329–353.
2.
Shimasaki S, Ling N: Identification and molecular characterization of insulin-like growth factor binding proteins (IGFBP-1, -2, -3, -4, -5 and -6). Prog Growth Factor Res 1991;3:243–266.
3.
Rosenfeld RG, Hwa V, Wilson L, López-Bermejo A, Buckway C, Burren C, Choi WK, Devi G, Ingermann A, Graham D, Minniti G, Spagnoli A, Oh Y: The insulin-like growth factor binding protein superfamily: New perspectives. Pediatrics 1999;104(suppl):1018–1020.
4.
Jones JI, Clemmons DR: Insulin-like growth factors and their binding proteins: Biological actions. Endocr Rev 1995;16:3–33.
5.
Bang P, Westgren M, Schwander J, Blum WF, Rosenfeld RG, Stangenberg M: Ontogeny of insulin-like growth factor-binding protein-1, -2, and -3: Quantitative measurements by radioimmunoassay in human fetal serum. Pediatr Res 1994;36:528–536.
6.
Baxter RC: Circulating binding proteins for the insulin-like growth factors. Trends Endocrinol Metab 1993;4:91–96.
7.
Ooi GT, Orlowski CC, Brown AL, Becker RE, Unterman TG, Rechler MM: Different tissue distribution and hormonal regulation of messenger RNAs encoding rat insulin-like growth factor binding proteins-1 and -2. Mol Endocrinol 1990;4:321–328.
8.
Delhanty PJD, Han VKM: The expression of insulin-like growth factor (IGF)-binding protein-2 and IGF-II genes in the tissues of the developing ovine fetus. Endocrinology 1993;132:41–52.
9.
Tanner JM: Growth and Adolescence, ed 2. Oxford, Blackwell, 1962.
10.
Barrios V, Argente J, Pozo J, Hervás F, Muñoz MT, Sánchez JI, Hernández M: Insulin-like growth factor I, insulin-like growth factor binding proteins, and growth hormone-binding protein in Spanish premature and full-term newborns. Horm Res 1996;46:130–137.
11.
Argente J, Caballo N, Barrios V, Muñoz MT, Pozo J, Chowen JA, Morandé G, Hernández M: Multiple endocrine abnormalities of the growth hormone and insulin-like growth factor axis in patients with anorexia nervosa: Effect of short and long-term weight recuperation. J Clin Endocrinol Metab 1997;82:2084–2092.
12.
Argente J, Caballo N, Barrios V, Pozo J, Muñoz MT, Chowen JA, Hernández M: Multiple endocrine abnormalities of the growth hormone and insulin-like growth factor axis in prepubertal children with exogenous obesity: Effect of short and long-term weight reduction. J Clin Endocrinol Metab 1997;82:2076–2083.
13.
Hernández M, Castellet J, Narvaíza JL, Rincón JM, Ruiz I, Sánchez E, Sobradillo B, Zurumendi A: Curvas y tablas de crecimiento, in Hernández M (ed). Fundación F. Orbegozo. Madrid, Garsi, 1988.
14.
Schrappe M, Reiter A, Sauter S: Concept and interim result of the ALL-BFM-90 therapy study in treatment of acute lymphoblastic leukemia in children and adolescents: The significance of initial therapy response in blood and bone marrow (in German). Klin Pädiatr 1994;206:208–221.
15.
Nunez SB, Municchi G, Barnes KM, Rose SR: Insulin-like growth factor (IGF-I) and IGF binding protein-3 concentrations compared to stimulated and night growth hormone in the evaluation of short children: A clinical research center study. J Clin Endocrinol Metab 1996;81:1927–1932.
16.
Underwood LE: Clinical uses of IGF-I and IGF binding protein assays; in Rosenfeld RG, Roberts CT Jr (eds): The IGF System: Molecular Biology, Physiology, and Clinical Applications. Totowa, Humana Press, 1999, pp 617–632.
17.
Smith WJ, Nam TJ, Underwood LE, Busby WH, Celnicker A, Clemmons DR: Use of insulin-like growth factor-binding protein-2 (IGFBP-2), IGFBP-3 and IGF-I for assessing growth hormone status in short children. J Clin Endocrinol Metab 1993;77:1294–1299.
18.
Clemmons DR, Snyder DK, Busby WH Jr: Variables controlling the secretion of insulin-like growth factor binding protein-2 in normal human subjects. J Clin Endocrinol Metab 1991;73:727–733.
19.
Blum WF, Horn N, Kratzch J, Jorgensen JO, Juul A, Teale D, Mohnike K, Ranke MB: Clinical studies of IGFBP-2 by radioimmunoassay. Growth Regul 1993;3:100–104.
20.
Argente J, Barrios V, Pozo J, Muñoz MT, Hervás F, Stene M, Hernández M: Normative data for insulin-like growth factors (IGFs), IGF-binding proteins, and growth hormone-binding protein in a healthy Spanish pediatric population: Age- and sex-related changes. J Clin Endocrinol Metab 1993;77:1522–1528.
21.
Cohick WS, McGuire MA, Clemmons DR, Bauman DE: Regulation of insulin-like growth factor-binding proteins in serum and lymph of lactating cows by somatotropin. Endocrinology 1992;130:1508–1514.
22.
Young SCJ, Clemmons DR: Changes in insulin-like growth factor (IGF)-binding proteins after IGF-I injections in noninsulin-dependent diabetics. J Clin Endocrinol Metab 1994;78:609–614.
23.
Jorgensen JO, Blum WF, Horn N, Moller N, Moller J, Ranke MB, Christiansen JS: Insulin-like growth factors (IGF) I and II and IGF binding proteins 1, 2 and 3 during low-dose growth hormone (GH) infusion and sequential euglycemic and hypoglycemic glucose clamps: studies in GH-deficient patients. Acta Endocrinol (Copenh) 1993;128:513–520.
24.
Suikkari AM, Koivisto VA, Rutanen EM, Yki-Jarvinen H, Karonen SL, Seppala M: Insulin regulates the serum levels of low molecular weight insulin-like growth factor-binding protein. J Clin Endocrinol Metab 1988;66:266–272.
25.
Frystyk J, Vestbo E, Skjaerbaek C, Mogensen CE, Ørskov H: Free insulin-like growth factors in human obesity. Metabolism 1995;44:37–44.
26.
Counts DR, Gwirtsman H, Carlsson LMS, Lesem M, Cutler G Jr: The effect of anorexia nervosa and refeeding on growth hormone-binding protein, the insulin-like growth factors (IGFs), and the IGF-binding proteins. J Clin Endocrinol Metab 1992;75:762–767.
27.
Pucilowska JB, Davenport ML, Kabir I, Clemmons DR, Thissa JP, Butler T, Underwood LE: The effect of dietary protein supplementation on IGFs and IGFBPs in children with Shigellosis. J Clin Endocrinol Metab 1993;77:1516–1521.
28.
Hernández M, Argente J, Navarro A, Caballo N, Barrios V, Hervás F, Polanco I: Growth in malnutrition related to gastrointestinal diseases: Coeliac disease. Horm Res 1992;38:79–84.
29.
Mohnike K, Kluba U, Blum WF, Aumann V, Vorwek P, Mittler U: Serum concentrations of insulin-like growth factors (IGF)-I and IGF-II and IGF binding proteins (IGFBP)-2 and IGFBP-3 in 49 children with ALL, NHL or solid tumors (in German). Klin Pädiatr 1995;207:225–229.
30.
Elmlinger MW, Sanatani MS, Bell M, Dannecker GE, Ranke MB: Elevated insulin-like growth factor (IGF) binding protein (IGFBP)-2 and IGFBP-4 expression of leukemic T-cells is affected by autocrine/paracrine IGF-II action but not by IGF type I receptor expression. Eur J Endocrinol 1998;138:337–343.
31.
Crofton PM, Ahmed SF, Wade JC, Stephen R, Elmlinger MW, Ranke MB, Kelnar CJH, Wallace WHB: Effects of intensive chemotherapy on bone and collagen turnover and the growth hormone axis in children with acute lymphoblastic leukemia. J Clin Endocrinol Metab 1998;83:3121–3129.
32.
Wang HS, Lim J, English J, Irvine L, Chard T: The concentration of insulin-like growth factor I and insulin-like growth factor binding protein-1 in human umbilical cord serum at delivery: Relation to fetal weight. J Endocrinol 1991;129:459–464.
© 2000 S. Karger AG, Basel
2000
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.